Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer

[1]  D. Cunningham,et al.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[3]  Yoon Young Choi,et al.  Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Väyrynen,et al.  Immune cell score in pancreatic cancer—comparison of hotspot and whole-section techniques , 2019, Virchows Archiv.

[5]  S. Jalkanen,et al.  Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors , 2019, Clinical Cancer Research.

[6]  R. Fossmark,et al.  Types of Gastric Carcinomas , 2018, International journal of molecular sciences.

[7]  R. Mehta,et al.  Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy , 2018, OncoTargets and therapy.

[8]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[9]  J. Ajani.  Faculty Opinions recommendation of Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[10]  L. Fashoyin-Aje,et al.  FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1 , 2018, The oncologist.

[11]  V. Canzonieri,et al.  Immunotherapy for Gastric Cancer: Time for a Personalized Approach? , 2018, International journal of molecular sciences.

[12]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[13]  P. Philip,et al.  Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial , 2018, JAMA oncology.

[14]  J. Ji,et al.  Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients , 2018, Oncoimmunology.

[15]  F. Roviello,et al.  Meta‐analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer , 2018, The British journal of surgery.

[16]  W. Guo,et al.  Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients , 2018, Oncotarget.

[17]  C. Maia,et al.  Variability of MMP/TIMP and TGF-β1 Receptors throughout the Clinical Progression of Chronic Venous Disease , 2017, International journal of molecular sciences.

[18]  Wei Wang,et al.  Galangin Reduces the Loss of Dopaminergic Neurons in an LPS-Evoked Model of Parkinson’s Disease in Rats , 2017, International journal of molecular sciences.

[19]  G. Kang,et al.  Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers , 2017, Oncotarget.

[20]  Y. Seto,et al.  Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications , 2017, Modern Pathology.

[21]  Xixi Zhao,et al.  Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature , 2017, Oncotarget.

[22]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[23]  S. Cai,et al.  ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer , 2016, Annals of surgery.

[24]  H. Yoon,et al.  The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. , 2016, Journal of gastrointestinal oncology.

[25]  R. Busuttil,et al.  Immunological battlefield in gastric cancer and role of immunotherapies. , 2016, World journal of gastroenterology.

[26]  Dajun Yang,et al.  Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. , 2015, International journal of clinical and experimental pathology.

[27]  T. Kuopio,et al.  Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer , 2015, British Journal of Cancer.

[28]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[29]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[30]  Roopma Wadhwa,et al.  Gastric cancer—molecular and clinical dimensions , 2013, Nature Reviews Clinical Oncology.

[31]  李晓星,et al.  Biomarker for gastric cancer , 2012 .

[32]  J. Väyrynen,et al.  An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer , 2012, Virchows Archiv.

[33]  Kay Washington,et al.  7th Edition of the AJCC Cancer Staging Manual: Stomach , 2010, Annals of surgical oncology.

[34]  M. Inoue,et al.  Gastric Cancer Working Group report. , 2010, Japanese journal of clinical oncology.

[35]  D. Cunningham,et al.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  O. Kallioniemi,et al.  Tissue microarrays (TMAs) for high‐throughput molecular pathology research , 2001, International journal of cancer.

[38]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[39]  R. Kelly.  Immunotherapy for Esophageal and Gastric Cancer. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[40]  A META-ANALYSIS OF THE LITERATURE , 2017 .

[41]  J. Barkin,et al.  Stomach , 2015, The American Journal of Gastroenterology.

[42]  PhD Kay Washington MD.  7th Edition of the AJCC Cancer Staging Manual: Stomach , 2010, Annals of Surgical Oncology.